Clavulanic acid
- Generic Name
- Clavulanic acid
- Brand Names
- Clavulin, Augmentin
- Drug Type
- Small Molecule
- Chemical Formula
- C8H9NO5
- CAS Number
- 58001-44-8
- Unique Ingredient Identifier
- 23521W1S24
- Background
Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with Amoxicillin or Ticarcillin to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces clavuligerus.When it is combined with amoxi...
- Indication
Clavulanic acid combined with other antibiotics is indicated to prevent the development of drug-resistant strains of bacteria and promotes their therapeutic antibacterial effects.
The following conditions, when they produced beta-lactamases, have been treated with a combination of amoxicillin and clavulanic acid or ticarcillin and clavulanic acid:
...
- Associated Conditions
- Infection Due to Escherichia Coli, Skin and skin structure infections, Acute Uncomplicated Pyelonephritis, Bronchitis, Haemophilus Influenzae, Lower Respiratory Infection, Otitis Media (OM), Moraxella catarrhalis, Upper Respiratory Tract Infection, Acute Cystitis, Cysto-Urethritis, Bone and Joint Infections, Sinusitis, Intraabdominal Infections, Tonsillitis, Proteus mirabilis, Lower Respiratory Tract Infection (LRTI), Neisseria Gonorrhoeae Infection, Susceptible Bacterial Infections, Pharyngitis, Bacterial infection due to streptococcus, group A, Urinary Tract Infection, Septicemia, Bacterial Infections, Bacterial Pneumonia, Streptococcus Pneumoniae, Gynecological Infection
- Associated Therapies
- -
Prophylactic Antibiotic in Non-complicated Low Risk Lap Cholecystectomy (LC)
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 200
- Registration Number
- NCT06193837
Effects of Antibiotic Prophylaxis on the Healing Parameters Following Surgical Crown Lengthening
- Conditions
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Biruni University
- Target Recruit Count
- 28
- Registration Number
- NCT05925179
Collaborative Urological Prosthetics Investigation Directive Research Group
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 800
- Registration Number
- NCT05100654
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Temple University
- Target Recruit Count
- 13
- Registration Number
- NCT04411914
- Locations
- 🇺🇸
Temple University Episcopal Hospital, Philadelphia, Pennsylvania, United States
Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid
- Conditions
- Interventions
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- Temple University
- Target Recruit Count
- 9
- Registration Number
- NCT03986762
- Locations
- 🇺🇸
Episcopal Hospital Medical Arts Building, Philadelphia, Pennsylvania, United States
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
- Conditions
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 30
- Registration Number
- NCT03713424
- Locations
- 🇺🇸
University of Missouri - Columbia, Columbia, Missouri, United States
Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps
- Conditions
- Interventions
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Loma Linda University
- Target Recruit Count
- 24
- Registration Number
- NCT02927834
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
- Conditions
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Temple University
- Target Recruit Count
- 10
- Registration Number
- NCT02563769
- Locations
- 🇺🇸
Temple University Hospital - Episcopal Campus, Philadelphia, Pennsylvania, United States
Short Duration Treatment of Non-severe Community Acquired Pneumonia
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Versailles Hospital
- Target Recruit Count
- 310
- Registration Number
- NCT01963442
- Locations
- 🇫🇷
Foch Hospital, Suresnes, France
🇫🇷CH Versailles, Le Chesnay, France
🇫🇷CHI Creteil, Creteil, France
Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 40
- Registration Number
- NCT01825408
- Locations
- 🇺🇸
Department of Otolaryngology-Head and Neck Surgery clinics at UNC Hospitals, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.